{"id":60858,"date":"2024-10-23T12:05:07","date_gmt":"2024-10-23T12:05:07","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/23\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/"},"modified":"2024-10-23T12:05:07","modified_gmt":"2024-10-23T12:05:07","slug":"acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/","title":{"rendered":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference"},"content":{"rendered":"<div>\n<p align=\"center\"><em>&#8211; Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer\u2019s disease<\/em><\/p>\n<p align=\"center\"><em>&#8211; Late-breaking presentation to be held Thursday, Oct. 31, at 9:30 a.m. CET<\/em><\/p>\n<p align=\"justify\">NEWTON, Mass., Oct.  23, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F58TuEqTog4M5ZHCG9_DlTfoPeSOSzMZRuBY3pHOzVSCu1IC6PJJq2Y1uzv061XE4W5JEdnqYFNIvQ-5k3cp525l-UwkToL0Lr32YYTOSbU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Acumen Pharmaceuticals, Inc.\">Acumen Pharmaceuticals, Inc.<\/a> (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced that it will present a late-breaking presentation featuring insights from its participant screening approach used in the ongoing Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193), at the 17<sup>th<\/sup> Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) conference taking place in Madrid, Spain, and online from Oct. 29 \u2013 Nov., 1, 2024.<\/p>\n<p align=\"justify\">Acumen will provide updated data on how it uses a validated research-use plasma pTau217 assay to screen potential participants in ALTITUDE-AD. Phosphorylated tau at position 217 is a biomarker that indicates AD pathology. The plasma pTau217 assay is being used as an initial screening tool to identify people who qualify for additional amyloid testing to determine eligibility for the ALTITUDE-AD trial.<\/p>\n<p align=\"justify\"><strong><u>Late-Breaking Presentation<\/u><\/strong><strong>: <\/strong><\/p>\n<p align=\"justify\"><strong>LB11 \u2013 ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer&#8217;s Disease<\/strong><br \/><strong>Date\/Time: <\/strong>Thursday, Oct. 31, 2024, 9:30 a.m. CET<br \/><strong>Location:<\/strong> Auditorium, Madrid Marriott Auditorium Hotel and Conference Center (Madrid, Spain)<br \/><strong>Presenter: <\/strong>Todd Feaster, Psy.D., Senior Clinical Research Scientist, Acumen Pharmaceuticals<\/p>\n<p align=\"justify\"><strong>About Sabirnetug (ACU193)<\/strong><\/p>\n<p align=\"justify\">Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (A\u03b2Os), which are a highly toxic and pathogenic form of A\u03b2, relative to A\u03b2 monomers and amyloid plaques. Soluble A\u03b2Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A\u03b2Os, sabirnetug aims to address the hypothesis that soluble A\u03b2Os are an early and persistent underlying cause of the neurodegenerative process in Alzheimer\u2019s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.<\/p>\n<p align=\"justify\"><strong>About ALTITUDE-AD (Phase 2)<\/strong><\/p>\n<p align=\"justify\">Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer&#8217;s disease. The study will enroll approximately 540 individuals with early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia due to AD). The global study is currently ongoing at multiple investigative sites located in the United States, Canada, UK, and the European Union. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.<\/p>\n<p align=\"justify\"><strong>About Acumen Pharmaceuticals, Inc.<\/strong><\/p>\n<p align=\"justify\">Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer\u2019s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P__EUzbIZmmQQeca2zlrDNKj4YueYPxxyCEl4OzDoBIityom0EzWEmTTE4CXsrs0ioS3IbWRXHK0fStKs9rsAlgyxcBPkWfyIG5Q80jfWfY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.acumenpharm.com\">www.acumenpharm.com<\/a>.<\/p>\n<p><strong>Investors: <\/strong><br \/>Alex Braun<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LUgkbvyziyDQvX7aA9OYvz5Z6TJraonwmuFJh9soZ0TnfulqRzjjde2KG6x5mJ6Hp8Xd_4pE-zizVKdg8ZlzH5H1Wk99wB8qrCsR1ar8hW8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"abraun@acumenpharm.com\">abraun@acumenpharm.com<\/a><\/p>\n<p><strong>Media:<\/strong><br \/>Jon Yu<br \/>ICR Westwicke <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F58TuEqTog4M5ZHCG9_DlZb6V3YyLR3tzmozWkW9tyL6iBaxTTiTz7Ir7SNiOaF4G4LwMo77Hl3vKzZOot554Z91buelQb5fyM08C666o2Y=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"AcumenPR@westwicke.com\">AcumenPR@westwicke.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDMyNGRiNzItNDI5My00NmEzLWE5YTUtYTVlOGU5NTA0MGE3LTEyMjIyMzU=\/tiny\/Acumen-Pharmaceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer\u2019s disease &#8211; Late-breaking presentation to be held Thursday, Oct. 31, at 9:30 a.m. CET NEWTON, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company [&#8230;]\n","protected":false},"author":1,"featured_media":60859,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference\" \/>\n<meta property=\"og:description\" content=\"&#8211; Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-23T12:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Acumen-Pharmaceuticals-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference\",\"datePublished\":\"2024-10-23T12:05:07+00:00\",\"dateModified\":\"2024-10-23T12:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\"},\"wordCount\":620,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\",\"name\":\"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-23T12:05:07+00:00\",\"dateModified\":\"2024-10-23T12:05:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference","og_description":"&#8211; Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early","og_url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-23T12:05:07+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Acumen-Pharmaceuticals-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference","datePublished":"2024-10-23T12:05:07+00:00","dateModified":"2024-10-23T12:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/"},"wordCount":620,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/","url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/","name":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-23T12:05:07+00:00","dateModified":"2024-10-23T12:05:07+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-deliver-late-breaking-presentation-at-17th-annual-clinical-trials-on-alzheimers-disease-ctad-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60858"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60858\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60859"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}